Effects of the long-term feeding of diets enriched with inorganic phosphorus on the adult feline kidney and phosphorus metabolism

Janet Alexander1*, Jonathan Stockman1, Jujhar Atwal1, Richard Butterwick1, Alison Colyer1, Denise Elliott2, Matthew Gilham1, Penelope Morris3, Ruth Staunton1, Helen Renfrew3, Jonathan Elliott4 and Phillip Watson1

1WALTHAM Centre for Pet Nutrition, Melton Mowbray, Leicestershire LE14 4RT, UK
2Royal Canin SAS, 650 Avenue de la Petite Camargue, 30470 Aimargues, France
3Renfrew Imaging, Grove Road, Bladon, Woodstock OX20 1RD, UK
4Department of Comparative Biomedical Sciences, Royal Veterinary College, University of London, London NW1 0TU, UK

Abstract
Renal disease has a high incidence in cats, and some evidence implicates dietary P as well. To investigate this further, two studies in healthy adult cats were conducted. Study 1 (36 weeks) included forty-eight cats, stratified to control or test diets providing 1-2 or 4-8 g/1000 kcal (4184 kJ) P (0 or approximately 3-6 g/1000 kcal (4184 kJ) inorganic P, Ca:P 1-2, 0-6). Study 2 (29 weeks) included fifty cats, stratified to control or test diets, providing 1-3 or 3-6 g/1000 kcal (4184 kJ) P (0 or approximately 1-5 g/1000 kcal (4184 kJ) inorganic P, Ca:P 1-2, 0-9). Health markers, glomerular filtration rate (GFR) and mineral balance were measured regularly, with abdominal ultrasound. Study 1 was halted after 4 weeks as the test group GFR reduced by 0.4 g/1000 kcal (4184 kJ) inorganic P, Ca:P 1-2, 0-6. A small, but significant, reduction in endogenous creatinine clearance and a slight decrease in plasma P were reported in cats offered the test diet containing 3-6 g/1000 kcal (4184 kJ), however the effect of inorganic P sources and Ca:P require further investigation.

Key words: Feline nutrition; Phosphorus; Mineral balance; Digestibility; Calcium:phosphorus ratio; Kidney disease

Chronic kidney disease (CKD) has a high prevalence in domestic cats, with approximately 33 % of those over the age of 12 years being affected(1). CKD is defined as a sustained decrease in renal function over at least 3 months and is an important cause of morbidity and mortality in the cat population. Both congenital and acquired disorders can lead to the development of CKD and acute kidney damage owing to urinary obstruction, nephrotoxins and pyelonephritis, or ischaemic injury can also progress to chronic disease(2). Although dietary P is essential for life, unrestricted P intake has been associated with the progression of existing renal disease(2,3). There is, however, little evidence to indicate adverse effects of high P intake in healthy adult cats. For this reason, there is currently no safe upper limit of dietary P cited in nutritional guidelines set out by the industry federation or association of American feed control officials (AAFCO)(4-6). The first study to suggest a link between high dietary P and reduced renal function in healthy adult cats was reported by Pastoor et al.(7). To evaluate the effects of high P intake, the authors fed a purified test diet containing 3-6 g P/1000 kcal (4184 kJ) with a Ca:P ratio of 0-3 for 4 weeks. A small, but significant, reduction in endogenous creatinine clearance and a slight decrease in plasma P were reported in cats offered the test diet compared with those offered P at a level of 2-3 g/1000 kcal (4184 kJ) or below(7). A neutral P balance was observed owing to an increase in both urinary and faecal P excretion when higher levels were fed, suggesting that P levels were regulated...
and excess P excreted rather than retained. These authors recommended that high dietary P levels should be discouraged owing to the associated reduction in plasma P concentrations and creatinine clearance. Subsequently, Dobenecker et al. (80) offered thirteen healthy adult cats a diet comparable to a home-prepared formulation with a total P of 3.0 g/1000 kcal (4184 kJ) with approximately 2.0 g/1000 kcal (4184 kJ) supplemented as calcium monophosphate and sodium dihydrogen phosphate (SDHP) with a Ca:P of 0:4. After 29 d of feeding, in agreement with the findings of Pastoor et al. (77), glucosuria and microalbuminuria were observed, creatinine clearance significantly decreased and blood urea nitrogen content increased (80).

It has been suggested previously in several species that P homeostasis is not only influenced by total dietary P content and the Ca:P, but also by the source of P (79-11). Dietary P provided by organic raw materials (e.g. poultry meal or meat and bone meal) has been shown to be less bioavailable than that arising from added inorganic sources (e.g. P containing mono and dibasic Na salts) (7,12). P-based additives are widely used in animal feed. Inorganic P from neutral monobasic/dibasic sodium phosphate. These authors (34·) compared a diet with 100 % P from an organic source (total P content 2·7 g/1000 kcal (4184 kJ), Ca:P 1:6) with a diet containing a similar total P (3·3 g/1000 kcal (4184 kJ) and Ca:P 1:4), but with 63·5 % P from neutral monobasic/dibasic sodium phosphate. These authors noted a greater percentage recovery of P in the urine when the high-inorganic P diet was fed compared with the organic P diet (34·9 % compared with 14·7 %). However, these findings may have been influenced by the higher Na level present in the inorganic P diet, which is known to increase P absorption by stimulating Na+-dependent uptake of phosphate (74·)

Together, these studies highlight a possible risk of changes in renal function when healthy adult cats are fed diets containing levels of P in excess of 3·0 g/1000 kcal (4184 kJ), or when high levels of P from inorganic sources are included in diets. However, the available evidence is not conclusive and the published data do not determine whether the reported changes exceeded normal reference ranges or have clinical relevance. The diets used in these studies do not represent commercially relevant formats being either purified (77·) or representative of ‘home-prepared’ diets (88). Therefore, to elucidate the effects of dietary P in cats, a long-term feeding study was initiated with the objective of evaluating the health effects of an extruded dry diet format containing total P and inorganic P (in the form of SDHP), at levels higher than previously reported, but possible in some commercial pet foods (15·). This study observed adverse changes in markers of renal health after 4 weeks of feeding and was terminated at this stage. We hypothesised that the adverse effects may have been due to the inclusion of highly available inorganic SDHP. Subsequently, a second 29-week study was initiated in which an extruded dry format diet with a lower inclusion of inorganic SDHP and a total P level equivalent to that previously reported by Pastoor et al. (77) was fed, in an attempt to identify a level of P inclusion resulting in no observed adverse effects level (NOAEL) in adult cats.

**Methods**

**Study design**

This work was approved by the WALTHAM Animal Welfare and Ethical Review Body and conducted under the authority of the Animals (Scientific Procedures) Act 1986.

**Study 1.** In a parallel design, forty-eight healthy neutered adult cats (twenty-three males and twenty-five females) aged between 1·7 and 9·1 years at the start of the study were stratified into two study groups and offered one of two extruded dry diet formats, differing in P content and Ca:P. Throughout an initial baseline period of 20 weeks, all cats were offered a control diet 74% lower in P than the test (Table 1), and baseline measurements were made within the final 4 weeks. Subsequently, test cats were offered a high-P test diet (Table 1), whereas the control cats remained on the control diet. After 4 weeks, measurements were repeated for both groups. Following review of these data, the study was terminated and the test cats returned to the control diet in week 6.

**Study 2.** In a parallel design, fifty healthy neutered adult cats (twenty-nine males and twenty-one females) aged between 1·4 and 7·8 years at the start of the study were stratified into two study groups and offered one of two extruded diets, differing in P content and Ca:P. Throughout an initial baseline period of 10 weeks, all cats were offered a lower P control diet (Table 1) and baseline measurements were made towards the end of this phase. Subsequently, test cats were offered a moderate P test diet (Table 1), whereas the control cats remained on the lower P control diet. Measurements were repeated after 2, 4, 8, 12, 20 and 28 weeks.

**Animals and housing**

Study 1 included forty-eight healthy neutered adult cats stratified into two study groups balancing energy intake, body weight (BW) and age. The control group was made up of twelve males and twelve females with a median starting age of 4·7 (1·7–8·1) years and the test of eleven males and thirteen females with a median starting age of 4·3 (1·7–9·1) years. Before selection, cats were health-screened by assessment of plasma biochemistry, haematology, urinary health parameters and abdominal ultrasound. Those with findings outside of normal range or considered abnormal by the site veterinarian were excluded, as were cats identified as having crystalluria, pre-existing uroliths, renaloliths or abnormal changes in renal size or echogenicity, as determined by a diplomate of the European
College of Veterinary Diagnostic Imaging (H. R.). Study 2 included fifty healthy neutered adult cats stratified into two study groups balancing energy intake, BW and age. The control group consisted of thirteen males and twelve females with a median starting age of 5–6 (1–7.7) years, and the test group was made up of fifteen males and ten females with a mean starting age of 4–6 (1–4–7.7) years. Before selection, cats were health-screened by applying the same criteria as for study 1. All cats were housed at the WALTHAM Centre for Pet Nutrition in social rooms, except during feeding or urine and faecal collection periods; to facilitate sample collection, they were individually housed in lodges. Cats received two 30-min meals (50% of maintenance energy requirement) per day, a pattern previously employed. Diet ingredients were made up of ground rice, cellulose, citric acid, vegetable fibre, sodium chloride, potassium citrate, calcium carbonate, zinc oxide, biotin, vitamin A palmitate, vitamin D3, vitamin E acetate, pyridoxine hydrochloride, thiamine hydrochloride, inositol, choline chloride (Metabolics Ltd) to ensure compliance with NRC (2006) adult cat recommendations for all nutrients except choline. Deionised water was freely available at all times. Initial energy requirements were determined by applying the NRC (2006) methodology.

Dietary phosphorus and the feline kidney

Dietary phosphorus and the feline kidney

Table 1. Diet composition*†‡§

| Diet | Study 1 control (g/1000 kcal (4184 kJ)) | Study 1 control (g/100 g) | Study 1 test (g/1000 kcal (4184 kJ)) | Study 1 test (g/100 g) | Study 2 control (g/1000 kcal (4184 kJ)) | Study 2 control (g/100 g) | Study 2 test (g/1000 kcal (4184 kJ)) | Study 2 test (g/100 g) |
|------|------------------------------------------|---------------------------|--------------------------------------|------------------------|------------------------------------------|---------------------------|--------------------------------------|------------------------|
| P    | 1.23                                     | 0.52                      | 4.78                                 | 1.93                   | 1.33                                     | 0.56                      | 3.59                                 | 1.49                   |
| Ca   | 1.33†                                    | 0.56†                     | 2.80‡                                | 1.13†                  | 1.58†                                    | 0.65                      | 3.34†                                | 1.39†                  |
| Ca:P | 1.08‡                                   | 0.59‡                     | 0.59‡                                | 1.19                   | 1.17‡                                    | 0.93                      | 0.93‡                                | 0.93‡                  |
| Na   | 3.11‡                                   | 1.31‡                     | 3.33‡                                | 1.35‡                  | 1.50‡                                    | 0.62                      | 1.35‡                                | 0.56‡                  |
| Mg   | 0.40‡                                   | 0.17‡                     | 0.18‡                                | 0.07‡                  | 0.25‡                                    | 0.10                      | 0.28‡                                | 0.12‡                  |
| Chloride | 4.63‡                                 | 1.95‡| 1.65‡                                | 0.67‡                  | 3.27‡                                    | 1.36                      | 1.99‡                                | 0.59‡                  |
| Vitamin | 254.22                                 | 106.84                    | 182.80                               | 73.52                  | 301.37‡                                  | 125.40                    | 183.45                               | 76.08                  |
| D3‡ | 42.0†                                   | 18.40†                    | 26.30†                               | 14.90†                 | 73.40†                                   | 11.20†                    | 15.50†                               | 10.00†                 |
| Protein | 68.13†                                  | 28.63†                    | 61.13†                               | 24.68†                 | 61.54†                                   | 25.61†                    | 64.27†                               | 26.63†                 |
| Fat  | 39.32†                                  | 16.53†                    | 39.88†                               | 16.10†                 | 39.76†                                   | 16.54†                    | 42.61†                               | 17.50†                 |
| Ash  | 19.29‡                                  | 8.11‡                     | 28.07‡                               | 11.33‡                 | 15.96‡                                   | 6.64                      | 21.53‡                               | 8.87‡                  |
| Crude fibre | 5.50‡                                  | 10.00‡                    | 5.20‡                                | 10.15‡                 | 7.34‡                                    | 3.06                      | 7.49‡                                | 3.15‡                  |
| Moisture | 12.52‡                                  | 0.00‡                     | 14.69‡                               | 0.00‡                  | 12.92‡                                   | 0.00†                     | 12.14§                               | 0.00§                  |
| PME§ | 420.27                                  | 403.76                    | 416.08                               | 412.00                 |                                         |                           |                                      |                        |

*PME, predicted metabolisable energy.
† Diet analysis g/1000 kcal (4184 kJ) or g/100 g DM.
‡ Value after supplementation of Ca at 200 mg/1000 kcal (4184 kJ).
§International units IU/1000 kcal (4184 kJ) or IU/100 g.
§‡ Calculated by proximate analysis to PME kcal/100 g according to LaFlamme (75).

In study 1, single batches of two extruded dry format experimental diets were specifically formulated for this study and manufactured (Royal Canin) using the same core recipe and raw materials, but with differing levels of P.

Both diets were composed of similar quantities of pork meal, pork fat and rind, poultry fat, soya and fish oils, yeast, beet pulp, ground rice, cellulose fibre, maize flour and gluten, potassium chloride, potassium citrate, sodium chloride, magnesium oxide, calcium bicarbonate (study 1), a vitamin premix, antioxidant and flavourings. The control diet contained 1.2 g P/1000 kcal (4184 kJ) (all provided from organic raw materials) and the higher P test diet contained 3.6 g P/1000 kcal (4184 kJ) (approximately 3.6 g/1000 kcal (4184 kJ) from inorganic sources) with 3.6 g Ca/1000 kcal (4184 kJ) (Ca:P 1:6 (Table 1). The additional Ca and P in the test diet were provided by inorganic calcium carbonate (2.6%) and SDHP (5.2%). However, to achieve a Ca:P of 0.6, the test diet was supplemented before feeding with calcium citrate malate (Metabolics Ltd) at a dose of 200 mg Ca/1000 kcal (4184 kJ). Diet analysis confirmed that the nutritional composition of both diets met NRC (2006) adult cat recommendations for all nutrients except choline in the test diet, which was supplemented with 118 mg/1000 kcal (4184 kJ) choline chloride (Metabolics Ltd) to ensure compliance (online Supplementary Table S1).

In study 2, single batches of two extruded dry format experimental diets were specifically formulated for this study and manufactured (Royal Canin) using the same core recipe used in study 1 and the same raw materials for both diets with additional pork meal added to the test diet. Control diet contained 1.5 g P/1000 kcal (4184 kJ) (all provided from organic raw materials) and the moderate P test diet contained 3.6 g P/1000 kcal (4184 kJ) (approximately 3.6 g/1000 kcal (4184 kJ) from inorganic sources) with 3.6 g Ca/1000 kcal (4184 kJ) (Ca:P 1:2) (Table 1). The additional Ca and P in the test diet were provided through organic sources: bone ash from protein meal supplemented with inorganic calcium carbonate (1.5%) and SDHP (2.2%). Both diets met NRC (2006) recommendations for adult cats (online Supplementary Table S1).

All diets were produced through a standard extrusion process commonly used in the pet food industry (17). Diet ingredients were mixed before being extruded and kibbled under identical processing conditions in a single-screw extruder (Royal Canin). All nutritional chemical analyses were carried out using Association of Official Agricultural Chemists (AOAC) procedures at Eurofins Ltd.

Measures

Intake was recorded on an individual basis as mass (g) of diet offered minus mass (g) of diet refused. BW was recorded weekly.
(in kg) on a standard scale (FB 34 3DE P top-pan balance; Sartorius).

**Mineral balance.** At baseline and after 4, 12, 20 and 28 weeks of feeding, five day total faeces and urine collections were carried out to determine mineral apparent digestibility. Samples were analysed for Ca using flame photometry and P using spectrophotometry at the Royal Canin SAS European Regional Laboratory. Faeces were stored frozen at −20°C in a sealed container until processing. Each pooled 5-d faecal collection was weighed and then freeze-dried (VirTis Benchtop BTP9ES Freeze Dryer, Biopharma Process Systems). Once dried, the faeces were reweighed and manually homogenised in a mortar and pestle; any foreign material was removed and weighed separately. A 20-g aliquot of the homogenate was analysed for moisture, crude fibre and ash content, according to methods described in the *Journal Official de l’Union Européenne* procedures (18); fat content was determined by acid hydrolysis followed by diethyl ether extraction and crude protein calculated from total N content by combustion using the Dumas principle according to Association Française de Normalisation (AFNOR ISO 16634-1:2008 November 2008). P content was determined via spectral photometry and Ca and Mg by flame photometry according to AFNOR methodology at Invivo Labs Chateau-Thierry. Apparent mineral digestibility (%) was calculated for Ca and P to represent the fraction of the minerals that were retained from the diet rather than being excreted in the faeces using the following formula:

\[
\text{Apparent digestibility} \% = \left( \frac{\text{intake} - \text{faecal excretion}}{\text{intake}} \right) \times 100.
\]

**Mineral balance (g) was also calculated for P and Ca as:**

\[
\text{Total mineral balance (g)} = \text{intake} - (\text{faecal excretion} + \text{urinary excretion})
\]

**Urine mineral content and relative super saturation (RSS).** All urine excreted over a 3-d (study 1) or 5-d (study 2) period was collected and urine pH assessed twice daily. The method for urine RSS analysis has been previously described (19). Samples were analysed for oxalate, citrate, pyrophosphate, K, Ca, Na, ammonium, chloride, sulphate and phosphate via HPLC. The concentrations of minerals were then analysed by SUPERSAT software (20) to calculate the RSS (activity product/solubility product) for struvite (magnesium ammonium phosphate (MAP)), calcium oxalate (CaOx) and brucite (study 2 only). The urine P and Ca content were determined via spectral photometry and flame photometry, respectively, according to AFNOR methodology at Invivo Labs Chateau-Thierry and used for calculation of the urinary fractional excretion of these minerals.

**Urinalysis.** At baseline and after 4 weeks of feeding (study 1) or baseline and after 4, 12, 20 and 28 weeks of feeding (study 2), a 5-ml freshly voided urine sample was collected from each cat, and creatinine, microalbumin, pH, urine-specific gravity, glucose, pH and urine protein creatinine ratio were measured (InSight MS-11 and MS-2 Vet urine strips; Woodley Equipment Company Ltd) within 30 min. Specific gravity was also determined using a refractometer (SinoTech RHCN-200ATC; SinoTech) and urine albumin and creatinine measured using the Beckman Coulter microalbumin (OSR6167) and creatinine (OSR6178) assays for the Olympus AU480 biochemistry analyser (Olympus Europe GmbH). The urine albumin:creatinine ratio (UACR) was then calculated for each sample.

**Blood-based measures.** At baseline and every 2–8 weeks thereafter, morning fasted (>12 h) blood samples were collected for the measurement of standard biochemistry and haematology, ionised Ca (iCa), vitamin D metabolites, TAG, markers of bone turnover, serum crosslaps (CTX) and bone-specific alkaline phosphatase (BAP), parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23). EDTA-treated blood was used to measure standard haematology parameters (leucocyte and erythrocyte counts, Hb concentration, haematocrit, platelet count, mean corpuscular volume, mean corpuscular Hb, number and percentage of lymphocytes, monocytes and granulocytes) via a Mythic 18 cell counter (Orphee).

Lithium-heparinised plasma was analysed to quantify standard biochemistry parameters (total protein, albumin, phosphate, alkaline phosphatase (ALP), alanine transaminase, aspartate aminotransferase, Ca, cholesterol, urea, creatinine, TAG and glucose). In study 1, this was carried out in-house using an AU480 (Olympus) analyser. In study 2, heparinised serum was sent to an external laboratory (IDEXX Laboratories) for biochemical analysis as in study 1 with the addition of symmetric dimethylarginine (SDMA) measurement. Serum was collected for the measurement of markers of bone turnover: BAP and CTX using the BAP MicroVue™ Quidel ELISA (TECO Medical Group) and CartiLaps® ELISA (Immunodiagnostik Systems Ltd), both according to the manufacturer’s instructions. In the Department of Comparative and Biomedical Sciences, Royal Veterinary College, London, EDTA plasma was analysed to quantify intact plasma FGF23 concentrations using a sandwich ELISA (Kainos Laboratories Inc.) as detailed by Geddes et al (20) and PTH concentrations by a total intact PTH immunoradiometric assay (Scantibodies Laboratory, Inc.) previously validated for use with feline samples (21). Serum was also collected for the measurement of the vitamin D metabolites 25-hydroxyvitamin D (25(OH)D) and 24,25-dihydroxyvitamin D (24,25(OH)2D) by liquid chromatography (LC)/MS (Waters Corp.). Total serum 1,25-dihydroxyvitamin D (1,25(OH)2D) levels were measured using a Micromass Quattro Ultima Pt Mass Spectrometer (Waters Corp.). Total serum 1,25-dihydroxyvitamin D (1,25(OH)2D) levels were measured using an EIA Kit (IDS Ltd). Ica analysis was conducted using heparinised whole blood in a Stat Profile Prime Critical Care analyser (Nova Biomedical).

Plasma and serum calcium–phosphorus (CaP) product (mmol²/l²) was calculated by multiplying plasma total Ca and inorganic P concentrations in mmol/l.

**Renal measures.** In study 1, at baseline and 5 weeks after diet change, and in study 2 at baseline, 5, 13, 21 and 29 weeks after
diet change, iohexol clearance tests were carried out as an estimate of glomerular filtration rate (GFR) using the method described by Finch et al. (23). Briefly, for topical anaesthesia, 2 ml of EMLA cream (2.5% lidocaine, 2.5% prilocaine; AstraZeneca) was applied to the skin over the cephalic veins and covered for 1 h before removal and aseptic preparation of the area with chlorhexidine gluconate. The cephalic vein was raised by pressure to the dorsal aspect of the foreleg and a catheter was inserted into the vein before flushing with 0.5 ml of heparinised saline (100 IU/ml of heparin in 0.9% saline; Wockhardt UK Ltd). A discard volume of 300 μl was removed from the catheter and 647 mg/kg iohexol (Omnipaque 300; Amersham Health) was administered over a 3-min period, followed by a heparinised saline flush. The completion of the injection represented time zero. Blood samples of 1 ml volume were collected via a cephalic catheter into serum tubes at 2, 3 and 4 h post infusion. Iohexol concentration in the serum of each cat at each time point was analysed using high-performance capillary electrophoresis (undertaken in the laboratories of deltaDOT Ltd and London BioScience Innovation Centre). Weight-adjusted clearance (in ml/kg per min) was calculated by the slope of the concentration gradient.

The fractional excretion of P (FEₚ) and Ca (FE₉ₐ) was calculated as the percentage filtered by the glomerulus excreted into the urine, expressed as a ratio to creatinine clearance as below:

\[
\% \, \text{FE} = \frac{\text{urinary concentration of } [X] \times \text{circulating creatinine concentration}}{\text{urinary concentration of creatinine} \times \text{circulating } [X] \text{ concentration}} \times 100
\]

Imaging: at baseline and at the end of both studies, general physical health examinations, whole-body radiographs and abdominal ultrasound scans were carried out to detect soft tissue mineralisation, urolithiasis or other pathologies. Radiographs of the abdomen were taken in ventrodorsal and right lateral recumbency, those of the thorax were taken in right lateral recumbency (AGFA CR 30-X, exposure range 46–64 kV, 2.36–4.73 mAs) and full abdominal ultrasound scans (GE Logiq-E with a linear probe 307 12L-RS, 5–13 MHz, 47 mm footprint) were performed, with the cats under sedation (induced through administration of 0.3 mg/kg butorphanol 0.025 mg/kg dexmedetomidine and reversed with 0.075 mg/kg atipamezol). All scans and interpretation of the radiographs were performed in R version 3.3.3(25) using libraries ‘lme4’ for linear mixed effects models(26), ‘multcomp’ for simultaneous inference of planned contrasts(27) and ‘ggplot’(28) for figures.

### Results

For behavioural reasons, occasional missed or partial samples occurred and sample numbers are presented in the relevant figures and tables.

#### Study 1

**Intake and body weight.** Increased incidence of vomiting was noted in the test group from week 1 of feeding and average daily energy intake (per kg BW) reduced significantly (P<0.001) in the test group from 43.14 (95% CI 39.23, 47.05) to 37.56 (95% CI 33.65, 41.47) kcal/kg BW (180.5 kcal/kg BW) and this change was significantly (P<0.001) different from the control group, which remained stable at 42.87 (95% CI 38.96, 46.78) kcal/kg BW and 43.93 (95% CI 40.02, 47.84) kcal/kg BW (179.4 kcal/kg BW) across the experiment. The mean BW in the test group reduced significantly (P<0.001) from baseline, whereas that of the control group did not change significantly (P>0.05).
not change \((P > 0.05)\) and this change was significantly \((P < 0.001)\) higher in the test group at week 4 (online Supplementary Table S2). When transferred to the test diet, mean P intake in the test group increased significantly \((P < 0.001)\) to 0.18 (0.17, 0.19) g/kg BW compared with 0.06 (0.04, 0.07) g/kg BW in the control (online Supplementary Table S2). Mean Ca intake was also observed to increase significantly \((P < 0.001)\) in the test group to 0.13 (0.12, 0.14) g/kg BW, compared with 0.06 (0.05, 0.07) g/kg BW in the control.

**Mineral apparent digestibility and balance.** Urinary and faecal P excretion in the test group increased significantly \((P < 0.001)\) from baseline and in comparison with the control group (Fig. 1(a)). Urinary excretion of Ca did not change from baseline in either group; however, faecal excretion increased \((P < 0.001)\) from the change in the control (Fig. 1(b)). Apparent digestibility (dietary intake minus faecal losses) of dietary P was not significantly \((P > 0.05)\) different between the control and test groups at baseline: 37.83 (32.34, 43.33) and 38.02 (32.41, 43.63)% respectively. After 4 weeks, P apparent digestibility in the test group increased by 11.28 (3.70, 18.86)% and this change was significantly \((P = 0.003)\) different from that in the control. In the test group, Ca apparent digestibility reduced significantly \((P = 0.001)\) from baseline over the feeding period, but this change was not significantly different \((P = 0.139)\) from the change in the control group.

**Glomerular filtration rate.** No difference between groups in GFR was observed at baseline (Fig. 2). Although GFR reduced significantly \((P < 0.05)\) in both groups over the feeding period, a significantly greater reduction \((P < 0.001)\) was observed in the test group compared with the control by 0.26 (0.11, 0.41) ml/min per kg (Fig. 2).
Blood biochemistry. At baseline, no significant differences were observed between diet groups in any parameter except iCa, which was significantly ($P=0.035$) higher in the control group by 0.021 (0.001, 0.041) mmol/l (Table 2). However, over the feeding period, control group iCa levels reduced to those of the test group, which did not change (Table 2). After 4 weeks of feeding, significant changes were observed in a number of parameters (Table 2). Plasma creatinine increased significantly in the test group by 24.95 (24-38, 25-52) µmol/l (Fig. 3(a)). In the test group, plasma urea increased significantly ($P<0.050$) by 1.38 (1.33, 1.44) mmol/l, whereas albumin levels decreased significantly ($P<0.050$) by 2.08 (2.05, 2.11) g/l (Fig. 3(b)). Plasma ALP concentration also increased significantly in the test group by 0.10 (0.09, 0.12) µkat/l (Table 2). No significant between group difference was observed in plasma total Ca levels, although those of the control group reduced significantly ($P=0.020$) (Fig. 3(c)). Plasma inorganic P concentration decreased significantly ($P<0.001$) in the test but not the control group over the feeding period by 0.40 (0.39, 0.41) mmol/l (Fig. 3(d)). The calculated plasma CaP product was not significantly different between groups at baseline (Table 2); however, after 4 weeks of feeding the test group CaP had reduced significantly ($P<0.001$) from 3.13 (2.88, 3.40) to 2.12 (1.97, 2.29) mmol/l²/l², and this change was significantly ($P<0.001$) different from the control group, which remained unchanged (Table 2). Additional blood biochemistry values can be seen in online Supplementary Table S3.

![Fig. 2. Study 1, glomerular filtration rate (GFR) determined by iohexol clearance (ml/min per kg) by study week and diet. Individual cat data are shown as small symbols and means as large symbols with 95% CI, n 23–24. * Significant difference in GFR relative to baseline diets ($P<0.05$). ▲ Control; ▼ test.](https://www.cambridge.org/core/terms)

### Table 2. Study 1 selected blood biochemistry, markers of bone metabolism and vitamin D metabolites

|                      | Control       | Test          | Mean   | 95% CI         | Mean   | 95% CI         | P     |
|----------------------|---------------|---------------|--------|----------------|--------|----------------|-------|
|                      | n 24          | n 24          |        |                |        |                |       |
| Albumin (g/l)        | 33.55±        | 32.57, 34.52  | 33.11a | 32.13, 34.08   |        |                | 0.005 |
| Baseline             | 32.44±        | 31.46, 33.43  | 31.03a | 30.09, 31.97   |        |                |       |
| Week 4               | 0.45±         | 0.37, 0.54    | 0.50a  | 0.41, 0.60     |        |                | <0.001|
| ALP (µkat/l)         |               |               | 0.60a  | 0.50, 0.73     |        |                |       |
| Baseline             | 1.27±         | 1.25, 1.28    | 1.24b  | 1.23, 1.26     |        |                |       |
| Week 4               | 1.24±         | 1.22, 1.25    | 1.24a  | 1.22, 1.25     |        |                | 0.007 |
| Ionised Ca (mmol/l)  |               |               |        |                |        |                |       |
| Baseline             | 6.34±         | 4.79, 8.39    | 7.47a  | 5.68, 9.83     |        |                | <0.001|
| Week 4               | 6.80±         | 5.14, 9.00    | 10.41a | 7.91, 13.69    |        |                |       |
| CTX (ng/ml)          |               |               |        |                |        |                | <0.001|
| Baseline             | 0.65±         | 0.50, 0.83    | 0.84a  | 0.66, 1.08     |        |                |       |
| Week 4               | 0.71±         | 0.55, 0.92    | 1.03a  | 0.81, 1.33     |        |                | 0.059 |
| Total 25(OH)D (nmol/l) |               |               |        |                |        |                |       |
| Baseline             | 131.60±       | 116.48, 148.67| 138.36a| 122.47, 156.31|        |                | <0.001|
| Week 4               | 144.20±       | 127.72, 162.79| 115.36a| 102.18, 190.24|        |                |       |
| Total 24,25(OH)₂D (nmol/l) |       |               |        |                |        |                |       |
| Baseline             | 28.52±        | 23.80, 34.17  | 27.68a | 23.10, 33.16   |        |                | <0.001|
| Week 4               | 25.06±        | 20.95, 29.97  | 27.12  | 22.68, 32.43   |        |                | 0.446 |
| C3-Epi-25(OH)₃D₃ (nmol/l) |               |               |        |                |        |                |       |
| Baseline             | 26.24±        | 22.78, 30.23  | 27.62a | 23.98, 31.81   |        |                | 0.007 |
| Week 4               | 31.94±        | 27.91, 36.69  | 24.93  | 21.70, 28.63   |        |                |       |
| 1,25(OH)₂D (pmol/l)  |               |               |        |                |        |                |       |
| Baseline             | 30.82±        | 24.48, 38.80  | 33.06a | 26.26, 41.62   |        |                | 0.092 |
| Week 4               | 33.16±        | 26.42, 41.62  | 27.68  | 22.05, 34.74   |        |                |       |

ALP, alkaline phosphatase; CaP, plasma Ca–P product; BAP, bone-specific alkaline phosphatase; CTX, serum crosslaps; 25(OH)D, 25-hydroxyvitamin D; 24,25(OH)₂D, 24,25-dihydroxyvitamin D; 1,25(OH)₂D, 1,25-dihydroxyvitamin D.

a,b Mean values within a row with unlike superscript letters were significantly different between test and control at baseline ($P<0.05$).

* A significant difference from baseline within group ($P<0.05$). $P$-value provides a comparison of the change from baseline at week 4, between test and control diet groups.
Vitamin D metabolites. In the test group, total 25(OH)D concentrations fell significantly ($P < 0.05$) from 138.36 (122.47, 156.31) nmol/l at baseline to 115.36 (102.18, 130.24) nmol/l at week 4 (Table 2). No significant ($P < 0.05$) changes were observed in levels of serum total 24,25(OH)2D over the 4-week feeding period (Table 2). Serum levels of C3-Epi-25(OH)D3 were not significantly different ($P > 0.05$) between groups at baseline, but after 4 weeks of feeding had increased significantly ($P = 0.01$) in the control group, whereas no change was observed in the test group (Table 2). No significant changes in serum 1,25(OH)2D were observed over the 4-week feeding period (Table 2).

Regulatory hormones and markers of bone turnover. Over the 4-week feeding period, levels of FGF23 increased significantly ($P < 0.001$) in the test group by 5.27 (4.14, 6.71)-fold (Fig. 4(a)). PTH also increased significantly in both diet groups; however, in the test group this increase was significantly ($P = 0.01$) greater by 4.15 (3.41, 5.06) pg/ml (Fig. 4(b)). BAP concentrations increased in the test group by 1.39 (1.29, 1.50)-fold, whereas those of the control group did not change (Table 2) and the difference in change from baseline between diets was significant ($P < 0.001$). Serum levels of CTx increased in both the control and test groups by 1.11 (1.02, 1.19)-fold and 1.23 (1.14, 1.32)-fold, respectively; therefore, the difference in change between groups did not meet the level of significance ($P > 0.05$) (Table 2).

Haematology. A total of five parameters were observed to change significantly over the feeding period. Mean corpuscular volume and mean corpuscular Hb reduced in both diet groups, although this was significantly greater ($P < 0.05$) in the test group (online Supplementary Table S4). Red cell distribution width and mean platelet volume both increased significantly in the test group, but not in the control (online Supplementary Table S4), whereas platelet distribution width reduced significantly only in the test group (online Supplementary Table S4).

Urinalysis. Although total daily urine volume increased significantly ($P = 0.007$) in the test group over the feeding period, no significant between diet difference in change from baseline was observed (Table 3). Urine specific gravity was
significantly lower in the test group compared with the control group at baseline \((P=0.04)\), but increased significantly \((P<0.05)\) by week 4 and no significant between diet difference in change from baseline was observed (Table 3). However, urine relative supersaturation for CaOx and MAP decreased significantly in the test group by 1.73 (1.38, 2.17) and 2.26 (1.39, 3.69)-fold, respectively (Table 3). Urine microalbumin levels increased significantly \((P<0.05)\) in the test cats (Table 3) as did UACR from 1.69 (1.07, 2.67) to 11.70 (7.41, 18.48) mg/g (Fig. 5).

![Figure 4](https://www.cambridge.org/core)
Examination of the whole-body radiographs did not indicate any evidence of mineralisation of soft tissues or skeletal changes. In all, two test cats (8%) had developed renoliths with parenchymal speckling and generalised increased echogenicity. In all, three cats in the control group were removed from trial after the baseline sample owing to behavioural unsuitability for sample collection. Data from these cats are not included in the analysis. In all, four cats were removed from the study before 28 weeks; one in the control group was removed in week 19 for behavioural reasons and its data were not included after this time. In all, three test group cats were removed after the 21-week sample point revealed changes in serum biochemistry (creatinine and urea outside of normal range) consistent with an adverse effect on renal function and their data were included up to and including week 21. For behavioural reasons, occasional missed or partial samples occurred for other measures and sample numbers are presented in the relevant figures and tables.

**Intake and body weight.** No significant between-group differences in BW were observed with mean values at baseline of 4.26 (3.88, 4.64) and 4.52 (4.15, 4.89) kg for the control and test groups, respectively, and 4.27 (3.89, 4.66) and 4.49 (4.12, 4.86) kg at week 29 (online Supplementary Table S5). No significant (P > 0.05) between-group differences in the change in energy intake were determined at any time (online Supplementary Table S5). After baseline, a significant increase (P < 0.001) in mean P intake to 0.16 (0.15, 0.17) g/kg was observed in the test group compared with the control, which did not change from a baseline level of 0.06 (0.05, 0.07) g/kg (online Supplementary Table S5). Mean Ca intake was also observed to increase significantly (P < 0.001) from baseline in the test group to a mean of 0.15 (0.14, 0.16) g/kg at week 28 from 0.07 (0.06, 0.08) g/kg.

**Mineral apparent digestibility and balance.** Urinary and faecal P excretion in the test group increased significantly (P < 0.001) from baseline and in comparison with the control group (Fig. 6(a)). The change from baseline in urinary Ca excretion was only significantly (P = 0.036) different between groups at week 28 (Fig. 6(b)). Faecal Ca excretion increased significantly (P < 0.001) in the test group compared with baseline and the control group. Apparent P digestibility at baseline was not significantly different (P = 0.996) between the control and test groups: 38.26 (32.14, 44.38) and 40.26 (34.27, 46.25)%, respectively. However, over the 29-week feeding period P apparent digestibility increased in both groups to 50.56 (43.48, 56.92)% in the control group and 51.53 (44.8, 58.25)% in the test group, and therefore no significant (P < 0.05) difference between diet difference in change from baseline was observed. Apparent Ca digestibility did not change significantly (P < 0.05) from baseline (14.33 (5.52, 23.13)% in the test group. However, in the control group Ca retention increased significantly (P < 0.001) from baseline by 23.05 (9.94, 36.15) to 37.37 (27.93, 46.81)% at week 28, a change significantly (P = 0.015) greater than in the test group.

Total P balance was not significantly different between the diet groups at baseline (P = 0.998) (Fig. 6(c)). From week 4 of the feeding period, total P balance increased significantly (P < 0.001) in the test group from 0.39 (0.18, 0.59) to 0.74 (0.52, 0.96) g/d at week 28, whereas that of the control group was significantly (P = 0.047) higher than baseline only at the final time point (Fig. 6(c)). Total Ca balance change from baseline was not significantly different between the diet groups at any time point (Fig. 6(d)).

**Glomerular filtration rate.** In both diet groups, no significant (P > 0.05) change from baseline was observed and no significant between-diet difference determined (Fig. 7).

**Blood biochemistry.** After 13 weeks of feeding, serum creatinine levels in the control group had fallen significantly (P < 0.001) and remained lower than at baseline for the rest of the feeding period. However, in the test group creatinine...
Fig. 6. Study 2, (a) daily faecal and urinary phosphorus excretion (g/kg), n=22–24, (b) daily faecal and urinary calcium excretion (g/kg), n=22–24, (c) phosphorus balance (g), n=22–24, (d) calcium balance (g), n=22–24, by study week and by diet. Individual cat data are shown as small symbols and means as large symbols with 95 % CI. * Significant between-diet difference in change from baseline (P<0.05). Total mineral balance (g) calculated as intake – (faecal excretion + urinary excretion).

Fig. 7. Study 2, glomerular filtration rate (GFR, ml/min per kg) by study week and diet. Individual cat data are shown as small symbols and means as large symbols with 95 % CI. * Significant between-diet difference in change from baseline (P<0.05). Total mineral balance (g) calculated as intake – (faecal excretion + urinary excretion).

Dietary phosphorus and the feline kidney

concentration did not change from baseline at any point (Fig. 8(a)). A significant (P<0.05) difference in change from baseline was observed between groups at weeks 13 and 21 (Fig. 8(a)), but not at week 28 (P=0.064) (Fig. 8(a)). Of the three cats that developed kidney disease, one was removed after serum creatinine levels were observed to increase from 190 to 283 µmol/l between weeks 13 and 21. The other two individuals were observed to have serum creatinine levels of 192 and 186 µmol/l at week 21 and were removed before week 28. Over the feeding period, serum urea levels fell significantly (P<0.001) below baseline in the control group from 13 weeks onwards (Fig. 8(b)), whereas those in the test group remained unchanged (P>0.05). A significant between-group difference in change in serum urea (P<0.05) was observed at weeks 21 and 28 (Fig. 8(b)). The three cats that developed kidney disease were observed to have serum urea levels of 12·1, 9·5 and 9·0 mmol/l at week 21. In both diet groups serum albumin levels decreased significantly (P<0.001) from baseline, although no significant (P>0.05) between-group difference in was observed (Table 4). Conversely, serum globulin levels increased significantly (P<0.001) from baseline in both groups; no significant between diet differences in change from baseline were detected (Table 4). Serum levels of SDMA did not change from baseline in either diet group over the course of the study and no between-group differences were observed (Table 4). However, fifteen cats in the control group were observed to have SDMA levels of between 0·75 and 1·09 µmol/l (15 and 22 µg/dl) at one or more time point, whereas seventeen test cats were determined to have levels of 0·73 and 1·14 µmol/l (15 and 23 µg/dl) at least once. The three cats that developed kidney disease were observed to have SDMA levels of 1·14, 0·84 and 0·74 µmol/l (23, 17 and 15 µg/dl) at week 21. Serum inorganic P concentrations decreased significantly (P<0.001) from a baseline mean of 1·42 (1·34, 1·52) to 1·22 (1·14, 1·3) mmol/l at week 28, whereas those of the control group did not change (Fig. 8(c)). The change in serum inorganic P concentration was therefore significantly different (P<0.010) in the test group compared with the control group from week 13 onwards (Fig. 8(c)). Serum levels of Ca fell...
significantly ($P<0.05$) from baseline in both groups, but a significant between-diet difference was only observed at week 28 ($P=0.002$, Fig. 8(d)). Post-baseline changes in serum cholesterol levels were observed in both groups, with significant ($P<0.05$) between-group differences detected between weeks 8 and 21 (online Supplementary Table S6). ALP concentrations were observed to have increased ($P=0.006$) from baseline in the test group at week 13, and this change was significantly different ($P=0.003$) from that in the control group at this time and at week 21 (online Supplementary Table S6). A transient difference ($P=0.006$) in change from baseline was detected in serum K and NaK ratio at week 13, but no other significant between-diet differences were observed in the biochemical parameters measured (online Supplementary Table S6). Plasma CaP product was not significantly different between groups at baseline (Table 4), however, over the feeding period this reduced significantly ($P<0.001$) in the test group from 3.6 (3.3, 3.9) mmol/l$^2$ at baseline to 2.9 (2.7, 3.1) mmol/l$^2$ at week 28 and this change was significantly ($P<0.001$) different from the control group (Table 4). Additional blood biochemistry values can be seen in online Supplementary Table S6.

**Vitamin D metabolites.** Serum total 25(OH)D concentrations in the test group fell significantly ($P<0.05$) from a baseline concentration of 137.89 (117-21, 162-22) to 123-58 (104-85, 145-66) nmol/l at week 28 (Table 4). However, this change was not significantly ($P>0.05$) different from that of the control group (Table 4). Total 24,25(OH)$_2$D serum concentration increased significantly ($P<0.05$) from baseline in the test group from 24-52 (19-43, 30-95) to 30-87 (24-36, 39-12) nmol/l at week 28, and this change was significantly ($P<0.05$) different from the control group from week 13 (Table 4). Serum levels of C3-Epi-25(OH)D$_3$ fell significantly from baseline in the test group from week 13 ($P<0.05$), although this change was not significantly different ($P>0.05$) from that in the control group at any point (Table 4). In the test group, other than a transient reduction ($P=0.012$) in week 4, serum levels of 1,25(OH)$_2$D did not change from baseline over the feeding period (Table 4). In the control group, serum levels of 1,25(OH)$_2$D were significantly lower than at baseline at weeks 13 and 28 and this change was significantly different ($P<0.05$) from that in the test group (Table 4).

**Regulatory hormones and markers of bone turnover.** Over the feeding period, serum levels of FGF23 in the test group increased from baseline by up to 2.91 (1.92, 4.42)-fold and this change was significantly ($P<0.05$) different from that in the control group at weeks 2, 4, 13 and 21 (Fig. 9(a)). Serum levels of PTH increased above baseline in the test group, although when compared with the control this change did not reach the level of statistical significance at time points other than weeks 21 and 28 (Fig. 9(b)). No significant between-diet differences in change from baseline were observed in the serum levels of CTx, although those of the control group fell significantly ($P<0.05$) (Table 4). No sustained change in BAP levels were determined in the test group, although levels reduced significantly ($P<0.05$) compared with baseline from week 8 onwards in the control group and this change was significantly different ($P<0.05$) to that of the test group from week 4 (Table 4).
Table 4: Study 2 selected blood biochemistry, markers of bone metabolism and vitamin D metabolites (Mean values and 95% confidence intervals)

|                      | Control                   | Test                  | P       |
|----------------------|---------------------------|-----------------------|---------|
|                      | Mean | 95% CI          | Mean | 95% CI          |
| **Albumin (g/l)**    |      |                 |      |                 |
| Baseline             |      |                 | 34.61+ | 33.43, 35.78   |
| Week 2               | 32.80+ | 31.43, 33.77 | 31.85+ | 30.73, 32.98   | 1.000   |
| Week 4               | 32.15+ | 30.97, 33.32 | 31.14+ | 30.01, 32.26   | 0.982   |
| Week 8               | 31.59+ | 30.41, 32.77 | 30.34+ | 29.21, 31.46   | 0.727   |
| Week 13              | 31.05+ | 29.87, 32.23 | 30.48+ | 29.36, 31.61   | 1.000   |
| Week 21              | 30.96+ | 29.78, 32.14 | 29.82+ | 28.70, 30.95   | 0.896   |
| Week 28              | 31.42+ | 30.24, 32.60 | 30.15+ | 29.00, 31.30   | 0.714   |
| **Globulin (g/l)**   |      |                 |      |                 |
| Baseline             | 31.99+ | 30.02, 33.95 | 33.10+ | 31.22, 34.99   |         |
| Week 2               | 34.89+ | 32.92, 36.85 | 35.15+ | 33.27, 37.03   | 0.931   |
| Week 4               | 33.27 | 31.31, 35.24 | 33.78 | 31.90, 35.66   | 0.995   |
| Week 8               | 34.23+ | 32.25, 36.21 | 34.39 | 32.51, 36.27   | 0.869   |
| Week 13              | 36.72+ | 34.75, 38.70 | 36.68+ | 34.69, 38.46   | 0.567   |
| Week 21              | 36.97 | 35.00, 38.95 | 37.84+ | 35.96, 39.73   | 1.000   |
| Week 28              | 36.34+ | 34.96, 38.31 | 37.38+ | 35.46, 39.30   | 1.000   |
| **SDMA (μmol/l)**    |      |                 |      |                 |
| Baseline             | 0.64+ | 0.56, 0.71    | 0.65+ | 0.58, 0.73     | 1.000   |
| Week 2               | 0.65 | 0.57, 0.72    | 0.66 | 0.59, 0.73     |         |
| Week 4               | 0.66 | 0.58, 0.73    | 0.62 | 0.55, 0.69     | 0.764   |
| Week 8               | 0.62 | 0.54, 0.70    | 0.61 | 0.54, 0.68     | 0.998   |
| Week 13              | 0.60 | 0.52, 0.67    | 0.61 | 0.54, 0.68     | 1.000   |
| Week 21              | 0.61 | 0.53, 0.68    | 0.63 | 0.56, 0.70     | 1.000   |
| Week 28              | 0.71 | 0.64, 0.79    | 0.63 | 0.55, 0.70     | 0.077   |
| **CaP (mmol²/l²)**   |      |                 |      |                 |
| Baseline             | 3.66+ | 3.39, 3.96    | 3.60+ | 3.34, 3.87     |         |
| Week 2               | 3.38+ | 3.13, 3.66    | 3.12+ | 2.90, 3.36     | 0.572   |
| Week 4               | 3.44 | 3.11, 3.72    | 3.13+ | 2.90, 3.37     | 0.295   |
| Week 8               | 3.27+ | 3.02, 3.54    | 2.92+ | 2.72, 3.15     | 0.118   |
| Week 13              | 3.40 | 3.14, 3.68    | 2.86+ | 2.65, 3.08     | <0.001  |
| Week 21              | 3.42 | 3.16, 3.70    | 2.93+ | 2.72, 3.15     | 0.003   |
| Week 28              | 3.54 | 3.29, 3.83    | 2.92+ | 2.70, 3.15     | <0.001  |
| **Ionised Ca (mmol/l)** | 20–22 | 1.27, 1.30 | 1.27 | 1.25, 1.29     | 0.999   |
| Baseline             | 1.29 | 1.26, 1.31    | 1.28 | 1.26, 1.30     | 0.999   |
| Week 2               | 1.28 | 1.26, 1.30    | 1.29 | 1.26, 1.31     | 0.998   |
| Week 4               | 1.30+ | 1.28, 1.32   | 1.29+ | 1.27, 1.31     | 0.996   |
| Week 8               | 1.30+ | 1.28, 1.32   | 1.28+ | 1.26, 1.30     | 0.581   |
| Week 13              | 1.30+ | 1.28, 1.33   | 1.30+ | 1.28, 1.32     | 1.000   |
| Week 21              | 1.31+ | 1.29, 1.33   | 1.27+ | 1.25, 1.30     | 0.003   |
| Week 28              | 1.31+ | 1.29, 1.33   | 1.27+ | 1.25, 1.30     |         |
| **BAP (UI)**         |      |                 |      |                 |
| Baseline             | 6.19+ | 4.53, 8.44    | 6.74+ | 5.00, 9.07     |         |
| Week 2               | 6.08 | 4.46, 8.30    | 6.93 | 5.15, 9.33     | 0.998   |
| Week 4               | 5.85 | 4.29, 7.98    | 7.80+ | 5.84, 10.60    | 0.003   |
| Week 8               | 5.46+ | 4.00, 7.45   | 7.41 | 5.50, 9.98     | 0.002   |
| Week 13              | 4.18+ | 3.06, 5.70   | 6.91 | 5.13, 9.30     | <0.001  |
| Week 21              | 4.94+ | 3.62, 6.74   | 7.63+ | 5.66, 10.30    | <0.001  |
| Week 29              | 4.73+ | 3.47, 6.46   | 6.29 | 4.66, 8.48     | 0.008   |
| **CTx (ng/ml)**      |      |                 |      |                 |
| Baseline             | 0.55+ | 0.40, 0.74    | 0.51+ | 0.38, 0.69     | 1.000   |
| Week 2               | 0.55 | 0.40, 0.74    | 0.51 | 0.39, 0.69     | 0.988   |
| Week 4               | 0.52 | 0.38, 0.71    | 0.52 | 0.39, 0.69     | 0.157   |
| Week 8               | 0.47+ | 0.35, 0.63   | 0.52 | 0.39, 0.70     | <0.001  |
| Week 13              | 0.39+ | 0.29, 0.53   | 0.52 | 0.39, 0.70     | 0.002   |
| Week 21              | 0.37+ | 0.27, 0.50   | 0.45 | 0.33, 0.61     | 0.055   |
| Week 29              | 0.37+ | 0.27, 0.50   | 0.42+ | 0.31, 0.57     | 0.055   |
Table 4. Continued

|                     | Control | Test   | P     |
|---------------------|---------|--------|-------|
| **Total 25(OH)D (nmol/l)** | Mean    | 95% CI | Mean   | 95% CI |       |
| Baseline            | 129.52a | 108.92, 154.01 | 137.89a | 117.21, 162.22 |       |
| Week 4              | 133.73  | 112.46, 159.02  | 125.95* | 107.06, 148.17  | 0.071 |
| Week 13             | 132.56  | 111.43, 157.55  | 125.59  | 106.76, 147.75  | 0.101 |
| Week 28             | 118.19  | 99.39, 140.54   | 123.58* | 104.86, 145.65  | 1.000 |
| **Total 24,25(OH)2D (nmol/l)** | Mean    | 95% CI | Mean   | 95% CI |       |
| Baseline            | 26.78a  | 20.89, 34.33    | 24.52a  | 19.43, 30.96    |       |
| Week 4              | 22.70*  | 17.71, 29.10    | 25.25   | 20.00, 31.88    | 0.133 |
| Week 13             | 24.67   | 19.25, 31.63    | 29.19*  | 23.12, 36.85    | 0.017 |
| Week 28             | 24.28   | 18.94, 31.12    | 30.87*  | 24.36, 39.13    | 0.001 |
| **C3-Epi-25(OH)D3 (nmol/l)** | Mean    | 95% CI | Mean   | 95% CI |       |
| Baseline            | 25.32a  | 21.50, 29.82    | 27.45a  | 23.55, 32.00    |       |
| Week 4              | 26.55   | 22.55, 31.27    | 24.15   | 20.72, 28.16    | 0.318 |
| Week 13             | 26.02   | 22.10, 30.64    | 22.99*  | 19.72, 26.80    | 0.169 |
| Week 28             | 21.10a  | 17.91, 24.84    | 22.24*  | 18.93, 26.12    | 1.000 |
| **1,25(OH)2D (pmol/l)** | Mean    | 95% CI | Mean   | 95% CI |       |
| Baseline            | 26.28a  | 20.18, 34.23    | 29.01a  | 22.67, 37.11    |       |
| Week 4              | 26.05   | 19.99, 33.95    | 24.28*  | 18.96, 31.11    | 0.106 |
| Week 13             | 21.20a  | 16.23, 27.67    | 29.01   | 22.66, 37.12    | 0.040 |
| Week 28             | 18.30a  | 14.01, 23.92    | 27.54   | 21.43, 35.38    | 0.004 |

SDMA, symmetric dimethylarginine; ALP, alkaline phosphatase; CaP, serum Ca–P product; BAP, bone-specific alkaline phosphatase; CTx, serum cross laps; 25(OH)D, 25-hydroxyvitamin D; 24,25(OH)2D, 24,25-dihydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D.

* Mean values within a row with unlike superscript letters were significantly different between test and control at baseline (P < 0.05).

* A significant difference from baseline within group (P < 0.05). P-value provides a comparison of the change from baseline at week 4, between test and control diet groups.

**Haematology.** Other than transient changes in granulocyte numbers, no significant between diet differences were observed in any of the haematological parameters measured (online Supplementary Table S7).

**Urinalysis.** No significant between-group differences in change in urine volume, specific gravity or urine pH was observed (Table 5). Urinary creatinine levels did not change from baseline in either group until week 28 when a reduction of 2-43 (2-16, 2-72) mmol/l was observed in the control group (Table 5). Urinary microalbumin levels in the test group increased significantly (P < 0.001) from 8-14 (5-49, 12-07) to 48-15 (32-08, 72-26) mg/l, although no change was observed in the control group (Table 5). Consequently, UACR in the test group was observed to increase (P < 0.001) from 2-37 (1-46, 3-84) to 14-38 (8-54, 24-21) mg/g at week 28, a change significantly (P < 0.001) different from that in the control (Fig. 10). Changes from baseline in urinary Ca, citrate and sulphate were not significantly different between groups at any time point (Table 5). Changes in urinary Mg, Na, urate and ammonium concentrations were small, but at some time points were significantly (P < 0.05) different between groups (Table 5). Urinary oxalate concentrations were higher in the test group than in the control by up to 0-64 (0-17, 1-12) mmol/l (Table 5) and the change from baseline in the test group was significantly (P < 0.05) different from that of the control. However, changes in urinary RSS for CaOx and struvite were not significantly different between groups (Table 5). In contrast, brushite urinary RSS increased significantly (P < 0.05) from baseline in the test group, and this change was significantly different (P < 0.001) from the control at week 12 (Table 5).
### Table 5. Study 2 urine analysis
(Mean values and 95% confidence intervals)

|                     | Control          | Test            | P    |
|---------------------|------------------|-----------------|------|
|                     | Mean 95% CI      | Mean 95% CI     |      |
| Daily total urine vol. (ml) |                  |                 |      |
| Baseline            | 39.67±          | 32.57±          | 0.944|
| Week 4              | 38.82±          | 28.41±          |      |
| Week 12             | 36.28±          | 28.98±          | 0.001|
| Week 20             | 33.00±          | 29.64±          |      |
| Week 28             | 33.81±          | 24.89±          |      |
| Urine pH            | n 21–22         | n 21–25         |      |
| Baseline            | 6.41±           | 6.26±           |      |
| Week 4              | 6.38±           | 6.34±           | 0.001|
| Week 12             | 6.32±           | 6.44±           | 0.015|
| Week 20             | 6.35±           | 6.46±           |      |
| Week 28             | 6.41±           | 6.59±           |      |
| Microalbumin (mg/l) | n 21–22         | n 21–25         |      |
| Baseline            | 7.17±           | 8.14±           |      |
| Week 4              | 8.33±           | 101.71±         | <0.001|
| Week 12             | 6.79±           | 44.52±          |      |
| Week 20             | 6.37±           | 40.54±          | <0.001|
| Week 28             | 8.23±           | 48.15±          |      |
| Creatinine (mmol/l) | n 21–22         | n 23–25         |      |
| Baseline            | 28.10±          | 30.40±          |      |
| Week 4              | 28.40±          | 31.70±          | 0.015|
| Week 12             | 28.40±          | 31.00±          |      |
| Week 20             | 27.70±          | 31.00±          |      |
| Week 28             | 25.60±          | 30.30±          |      |
| Specific gravity    | n 20–22         | n 20–25         |      |
| Baseline            | 1.0±            | 1.0±            |      |
| Week 4              | 1.0±            | 1.0±            |      |
| Week 12             | 1.0±            | 1.0±            |      |
| Week 20             | 1.0±            | 1.0±            |      |
| Week 28             | 1.0±            | 1.0±            |      |
| RS CaOx             | n 18–22         | n 15–25         |      |
| Baseline            | 3.48±           | 4.04±           |      |
| Week 4              | 2.79±           | 2.31±           |      |
| Week 12             | 2.67±           | 3.24±           |      |
| Week 20             | 3.95±           | 3.49±           |      |
| Week 28             | 4.31±           | 3.20±           |      |
| RSS MAP              | n 18–22         | n 15–25         |      |
| Baseline            | 0.86±           | 1.11±           |      |
| Week 4              | 0.87±           | 1.15±           |      |
| Week 12             | 0.84±           | 1.32±           |      |
| Week 20             | 1.24±           | 2.03±           |      |
| Week 28             | 0.93±           | 1.61±           |      |
| Oxalate (mmol/l)    | n 18–22         | n 15–25         |      |
| Baseline            | 1.99±           | 2.10±           |      |
| Week 4              | 2.08±           | 2.64±           | <0.001|
| Week 12             | 2.08±           | 2.57±           | <0.001|
| Week 20             | 2.22±           | 2.79±           | <0.001|
| Week 28             | 2.16±           | 2.80±           | <0.001|
| RSS BRU             | n 18–22         | n 15–25         |      |
| Baseline            | 0.55±           | 0.74±           |      |
| Week 4              | 0.42±           | 0.81±           |      |
| Week 12             | 0.40±           | 1.15±           | <0.001|
| Week 20             | 0.63±           | 1.29±           |      |
| Week 28             | 0.63±           | 1.07±           |      |
| Urinary Ca (mmol/l) | n 20–22         | n 19–25         |      |
| Baseline            | 0.74±           | 0.92±           |      |
| Week 4              | 0.61±           | 0.67±           | 0.969|
| Week 12             | 0.57±           | 0.82±           | 0.922|
| Week 20             | 0.89±           | 0.93±           | 0.857|
| Week 28             | 0.99±           | 0.87±           | 0.122|
| FEa (%)             | n 19–22         | n 17–25         |      |
| Baseline            | 20.53±          | 23.34±          |      |
| Week 4              | 21.50±          | 25.22±          | <0.001|
| Week 12             | 21.30±          | 75.22±          | <0.001|
| Week 20             | 19.53±          | 75.14±          | <0.001|
| Week 28             | 20.04±          | 75.13±          | <0.001|
Discussion

In study 1, feeding cats an extruded diet with a total P content of 4.8 g/1000 kcal (4184 kJ) and Ca:P of 0.6 led to a series of adverse health effects within 4 weeks, including reduced appetite, increased incidence of vomiting, weight loss and changes in renal echogenicity indicative of structural abnormalities. In agreement with findings of Pastoor et al. and Dobenecker et al., elevated serum creatinine concentrations were observed and these were accompanied by a persistent reduction in GFR generally indicates direct damage to the renal tubular cells leading to loss of functioning nephrons. If the initial damage is to the tubular cells, the cells may desquamate into the tubular lumen causing obstruction and back flow of filtrate into the peritubular interstitium, thus increasing glomerular pressure and decreasing GFR. In turn this leads to a reduction in creatinine and urea clearance from the blood and serum levels increase as observed in study 1. A significant reduction in serum albumin levels was also observed in the test group, possibly indicating impairment in the kidney’s ability to retain this protein. However, as only a relatively small corresponding increase in urine microalbumin was observed, this may have been because of losses due to blood sampling, as well as reduced production due to decreased food intake. Haematological changes observed in the study 1 test group were similar to those reported in cats suffering from hyperthyroidism – for

Histology. In week 27, following a pre-defined clinical management pathway, one cat from the test group was euthanised after developing acute azotaemia that did not respond to treatment. Post-mortem and histological investigations were carried out. Macroscopically the kidney surface was observed to be irregular and within the cortex several white radial stripes were observed with chronic inflammation and fibrosis. Lesions were radially distributed supporting the presence of renal infarcts. Inflammatory cells, multifocal flattening of the tubule epithelial lining, accumulation of necrotic debris, dystrophic calcifications and crystals were observed under microscopic examination. The inflammatory infiltrate was noted to extend into the medulla, pelvis and renal capsule. Von Kossa staining gave a positive signal in the foci of tubular necrosis, although negative intratubular crystals were also observed.

Abdominal ultrasound, whole-body radiographs and post-mortem histology. At the end of the study, ultrasound examination revealed that fifteen cats (60%) in the test group had developed renaloliths compared with six cases in the control group (27%). Evidence of changes in kidney echogenicity indicative of structural changes were not observed in the control group, but were observed in nine test cats (36%). Of these, one test cat was observed to have developed narrow and four broad renal cortical RS, whereas three were observed to have parenchymal speckling, hyperchoic medullary radiating linear echoes or generalised increased echogenicity. In all, five test cats (20%) were identified as having both changes in echogenicity with renaloliths present, two of which had also developed pyelectasia. Examination of the whole-body radiographs did not indicate evidence of any soft tissue mineralisation outside of the kidney or skeletal changes.

Table 5. Continued

| FE_{Ca} (%) | Control Mean 95 % CI | Test Mean 95 % CI | P |
|-------------|----------------------|------------------|---|
| Baseline    | 0.15a 0.11–0.22      | 0.17a 0.12–0.24  |   |
| Week 4      | 0.12 0.09–0.18       | 0.12* 0.09–0.18  | 0.986 |
| Week 12     | 0.12 0.08–0.17       | 0.16 0.11–0.23   | 0.903 |
| Week 20     | 0.17 0.12–0.25       | 0.18 0.13–0.26   | 0.999 |
| Week 28     | 0.20 0.14–0.29       | 0.17 0.12–0.24   | 0.322 |

* A significant difference from baseline within group (P<0.05). 
P-value provides a comparison of the change from baseline at week 4, between test and control diet groups.

Fractional excretion. Calculated FE_{Ca} was not significantly different between groups at baseline, but after 4 weeks of feeding had increased significantly (P<0.001) in the test group from 23-34 (95 % CI 20-41, 26-69) to 75-22 (95 % CI 65-18, 86-80) % (Table 5). This increase was sustained for the rest of the feeding period and was significantly different (P<0.001) from that in the control group (Table 4). FE_{Ca} was not significantly different between groups and did not change significantly in either group over the feeding period (Table 5).

Abdominal ultrasound, whole-body radiographs and post-mortem histology. At the end of the study, ultrasound examination revealed that fifteen cats (60 %) in the test group had developed renaloliths compared with six cases in the control group (27 %). Evidence of changes in kidney echogenicity indicative of structural changes were not observed in the control group, but were observed in nine test cats (36 %). Of these, one test cat was observed to have developed narrow and four broad renal cortical RS, whereas three were observed to have parenchymal speckling, hyperchoic medullary radiating linear echoes or generalised increased echogenicity. In all, five test cats (20 %) were identified as having both changes in echogenicity with renaloliths present, two of which had also developed pyelectasia. Examination of the whole-body radiographs did not indicate evidence of any soft tissue mineralisation outside of the kidney or skeletal changes.
example, erythrocyte poikilocytosis indicated by changes in mean corpuscular volume, mean corpuscular Hb, reduced erythrocyte distribution width and mean platelet volume. These changes may have been because of haemodynamic disturbance due to reduced GFR\(^{32}\). The observed alterations to serum and urinary biochemistry are indicative of stage 2 kidney disease classified using the International Renal Interest Society scale\(^{33}\) and are supported by the changes in renal morphology identified by ultrasonography. Subsequent monitoring has indicated that these changes are persistent, but not progressive.

Subsequently, study 2 was undertaken with the aim of determining a NOAEL for dietary P. In this study, clinically relevant changes in markers of kidney function were not apparent in the majority of cats offered a test diet containing 3.6 g/1000 kcal (4184 kJ) of P and a Ca:P of 0.9. The mean GFR and circulating concentrations of serum creatinine, urea and SDMA did not change in the test group over the course of the feeding period. It is also of note that serum levels of creatinine and urea fell in the control group, possibly owing to differences between the control diet and the standard diets the cats were habituated to before the study, although it might be expected that adaptation would have taken place over a shorter time period. P regulatory factors, FGF23, PTH, iCa and vitamin D remained within published normal ranges in all but three cats throughout the second study\(^{30,34,35}\). However, in common with the first study, FGF23 and PTH levels increased significantly in response to the increased P intake, although the changes were less marked. Notwithstanding the lesser degree of adaptive changes observed in study 2 and the stability of mean GFR, the incidence of kidney stones and renal structural changes, as determined by ultrasonography, were observed to be higher in the test group. In addition, three cats developed signs of renal dysfunction towards the end of the feeding period, with clinically relevant changes from week 21 of feeding. Taking these observations together, it was not possible to establish a NOAEL for dietary P.

The bioavailability of dietary P is not only influenced by the P content of the diet, but the ratio of Ca:P and source of P have also been demonstrated to play important roles in absorption\(^{9-11}\). Here, in study 1, extra Ca in both organic (bone and meal meal) and inorganic (calcium carbonate) forms was added to balance the P content of the test diets at the desired ratio. Dietary P provided by organic raw materials (e.g. bone meal, poultry meal or P bound by phytates) is less bioavailable than that arising from added inorganic sources (e.g. P containing mono and dibasic Na salts)\(^{7,12}\). Phosphates are widely used in commercial human and pet food manufacturing, where they serve a number of processing functions and as a source of required dietary P\(^{13}\). Such P salts easily dissociate, solubilise and are readily absorbed in the intestinal tract; hence, P absorption can be greatly influenced by the chemical form ingested, with both circulating P concentration and urinary P excretion influenced by differences in dietary P availability\(^{12}\). Evidence suggests that over 90% of inorganic P may be bioavailable, compared with between 40 and 60% for naturally occurring sources\(^{10}\); the proportion of dietary P coming from inorganic sources probably contributed to the effects seen after consumption of high P diets in the present studies, as well as those reported by Pastoor et al.\(^{17}\) and Dobenecker et al.\(^{38}\). The test diets used here were formulated using relatively high levels of inorganic SDHP, which has been reported to be highly bioavailable and to have a greater effect on renal parameters than calcium monophosphate\(^{30}\). Inorganic neutral monobasic/dibasic sodium phosphates have been observed to increase urinary P concentration more than those originating from organic dietary P sources\(^{12}\), and the higher level of dietary Na associated with these salts may stimulate of Na\(^+\)-dependent uptake of phosphate\(^{14}\). This action could have exacerbated the adverse effects of P intake in the studies presented here and particularly in study 2 when total P level was moderate. However, it is unlikely that Na levels alone induced the renal changes observed here. A study on the effects of dietary salt intake on renal function in healthy aged cats using a test diet at a similar level of Na inclusion did not induce deleterious effects on renal function or changes in plasma P, creatinine and PTH over a 2-year feeding period\(^{37}\). In a recent study of the post-prandial effects of dietary P in cats, Coltherd et al.\(^{38}\) observed that plasma P profiles are responsive to changes in dietary P content and that inorganic P content drives this response in a dose-dependent manner. These authors report that feeding diets with a high inclusion of SDHP and a Ca:P <1:0 induced a significant increase in postprandial plasma P levels that was sustained for 6 h. Our findings therefore support other reports indicating that diets including high levels of P from inorganic salts may have adverse effects on renal health in healthy cats\(^{12,36,39,40}\).

Circulating P levels are regulated by a number of hormones including FGF23 and PTH. In both studies, when high levels of P were ingested, levels of these hormones increased possibly in an attempt to maintain homoeostasis. PTH and FGF23 reduce reabsorption of phosphate in the proximal tubule, resulting in increased P concentration in the tubule, potentially leading to crystallisation\(^{41}\). PTH acts by reducing sodium phosphate cotransporter expression on the apical membrane of the proximal tubule and induces increased urinary P excretion\(^{42}\), as observed here. FGF23 and its co-factor, klotho, bind to FGF receptors type 1 in the proximal tubule and inhibit synthesis of the sodium phosphate cotransporter and 1α-hydroxylase, an enzyme involved in hydroxylation of 25OHD (calcifediol) to 1,25(OH)\(_2\)D (calcitriol the bioactive form of vitamin D)\(^{43}\). As a result, more P would be expected to be excreted in urine and, owing to reduced levels of vitamin D, less P absorbed from the intestine, hence reducing the circulating P level. In the current studies, although urinary P concentration increased in the test groups as might be expected, there was no reduction in P apparent digestibility. While remaining within the normal range (0.8–1.9 mmol/l), circulating P concentrations in both studies were observed to reduce, possibly indicating an over-compensation in urinary excretion. In the first study, owing to the relatively low circulating P levels compared with the high urinary excretion observed, calculated FE increased significantly over the feeding period to levels much higher than those reported as normal for cats (<7%\(^{34,45}\) and considered physiologically impossible as net tubular secretion of phosphate does not occur. This may be because the fasting levels of circulating P measured in the study are not indicative of transient postprandial changes in concentration. It has been reported in dogs that FE of a number of minerals is
significantly higher after feeding, and postprandial measurements may offer further information on adaptations made in response to dietary intake. In the second study, while FEP increased significantly in response to the more moderate levels of dietary P, although still likely to be an over-estimation owing to postprandial fluctuations in plasma P concentration, values were closer to the reported physiological maximum. Other minerals may also exert effects on P regulation – for example, Mg and P metabolism have previously been linked and hypomagnesaemia has been associated with raised FGF23 production and the progression of CKD in cats. However, here dietary Mg levels, while meeting nutritional requirements, were not fixed and neither serum nor faecal Mg levels were assessed; hence, the contribution of this mineral cannot be interrogated.

P absorption in the gut is regulated by the effect of 1,25(OH)2D on intestinal NaPi-2b transporters. However, in both studies, the expected suppression of serum 1,25(OH)2D by FGF23 was not observed, although circulating levels of its precursor 25(OH)D did reduce significantly in the test groups. Increased PTH owing to ingestion of significant quantities of bioavailable P could counteract the effect of FGF23 by upregulating synthesis of 1,25(OH)2D in an attempt to increase Ca absorption. Although in the first study Ca balance became negative, no significant reduction in serum Ca or iCa was observed and FE Ca remained within reported normal range. In the absence of changes in iCa, it is, however, possible that PTH secretion could be increased owing to transient fluctuations in postprandial extracellular P concentration. Such postprandial changes in circulating iCa or P, although sufficient to induce PTH, would not be detected in the fasted blood samples taken in the current study. Circadian patterns of serum P, which can be modified by intake, have been observed in humans and it has been suggested that studies targeting intestinal phosphate absorption should consider afternoon phosphate measurements. Coltherd et al. have reported that feeding a diet with a high inclusion of SDHP decreased iCa and increased PTH postprandially. It has also been reported that stimulation of PTH by hypocalcaemia or hyperphosphataemia may be counteracted by balancing dietary Ca:P. This postulated protective effect of Ca:P is supported by Coltherd et al., who observed altered iCa and PTH response when a diets of similar SDHP concentration but differing Ca:P was fed. PTH is also reported to increase the rate of bone resorption and remodelling, a recognised consequence of increased P load. After ingestion of excess P, deposition of Ca and P in bone may increase hypocalcaemia and raise markers of bone turnover. In study 1, cats offered the test diet were observed to have increased levels of ALP and BAP. ALP breaks down pyrophosphate or \( \beta \)-glycerophosphate into inorganic phosphate essential to osteoblast differentiation and mineralisation and may also play a role in the intestinal absorption of inorganic P to facilitate transport. However, such changes were not observed in study 2, when a more moderate amount of P was fed and no skeletal mineralisation or demineralisation was observed in radiographs from either study. Despite this, Ca balance was observed to become negative in the first study, indicating increased secretion of Ca into the intestine – a phenomenon previously correlated with high P intake. This endogenous Ca is probably released from bone, which may be evidenced by the raised levels of ALP owing to increased bone remodelling.

Increased total P burden can induce soft tissue mineralisation in the kidneys and other organs and deleterious effects of phosphate accumulation can be a direct consequence of calcium phosphate precipitates in the tissues. However, in both studies reported here the fasting CaP product was observed to be well below the level at which mineralisation is reported to occur (70 mg\(^2\)/dl\(^2\), 5-6 mmol/L\(^2\)). The reduction in serum P concentration observed in the test groups actually lowered CaP, which would be expected to reduce the risk of mineralisation. In the urinary tract, calculi are the most common form of mineralisation and cortical nephrocalcinosis may appear as increased echogenicity in or around the cortex. In both of the current studies, changes in renal echogenicity consistent with mineralisation were observed and histological examination of renal tissue from one cat indicated the presence of crystals and Ca deposits. P intake in cats has previously been reported to play a role in urolithiasis, and in study 2 a higher incidence of renolith formation was observed in the test group. P is a component of struvite (MAP) and diets with a high P content have been associated with increased risk of struvite stone formation. However, no sustained increase in urinary struvite RSS was observed with mean levels remaining at less than that regarded as metastable (≤2.5). Crystallisation required for struvite renolith formation only occurs when mineral concentrations are sufficiently high and the urine pH is neutral or alkaline. Here, mean urinary pH was between 6.3 and 6.6 – in the range recommended to reduce the risk of struvite crystal formation in cats. CaOx is reported as the most common mineral found in feline renoliths. In the second study, urine concentrations of oxalate were significantly increased in the test group, although mean urinary RSS for CaOx was similar between groups and below 10, a level reported to reduce the risk of stone formation. In cats primary hyperoxaluria has been noted to result in the presence of birefringent crystals in the tubules and renal fibrosis; however, such cases are rare and linked to a genetic disease similar to human primary hyperoxaluria type 2. In the current study, urinary RSS for brushite (CaHPO\(_4\).2H\(_2\)O), another stone-forming mineral, was increased significantly in the test group compared with the control group. Although brushite stones are normally uncommon in cats, in humans metabolic abnormalities such as renal tubular acidosis and primary hyperparathyroidism are common in brushite stone disease. Furthermore, humans who form brushite renoliths demonstrate renal cellular damage and kidney cell injury is associated with the presence of brushite crystals. It has been proposed that a physiological change or insult causing loss of collecting duct cell pH regulation can trigger crystallisation resulting in cell injury and death. In alignment with the histological observations made in study 2, the crystallisation process in humans was observed to enlarge the collecting duct and to initiate interstitial inflammation. It is possible that in the current studies the levels of P reaching the kidney could initiate a similar process, with length of exposure to the P a contributing factor as increased incidence of renolith formation was only observed in study 2. However, as renoliths were also identified in a number of control cats, the effects of other promoters of crystal precipitation and aggregation cannot be
excluded. While little information is available on renolith incidence and development in the general cat population, the development of renoliths in the control group over the feeding period was surprising and higher than that observed in a comparable population of colony cats (approximately 11% of cats)(72). The incidence of renolith formation could possibly have been influenced by the lower P content of the control diet as a study evaluating dietary risk factors for CaOx urolithiasis reported that cats consuming diets with lower P content had increased risk for CaOx urolithiasis(69). However, the control diet was at a P level similar to commercial diets designed for senior cats and not reported to induce negative effects on renal function(75). One shortcoming of the study is the lack of renolith analysis to confirm chemical composition and indicate mechanism of formation. However, surgical intervention to remove the stones was deemed not to be in the therapeutic interest of the cats by the attending veterinary team. It is possible that the moderate protein levels of the diets used could have also influenced the outcome of these studies. Although the formulations were based on standard extruded commercial products, protein inclusion was limited owing to the requirement to produce diets with similar nutrient levels other than P and Ca inclusion. Furthermore, if high-protein inclusion study diets had been used, this could have been a confounding factor in assessment of the impact of dietary P on renal health, as a recent retrospective study has identified a link between high protein intakes and CKD in cats(76). Although the test diet offered in the first study and the control diet offered in the second study were, respectively, 1.3 and 0.4% lower than the AAFCCO minimum for adult maintenance (26% of DM)(6), all the diets used were at least 20% above the NRC (2006) adult protein RA(45). It would therefore seem unlikely that physiologically meaningful protein deficiency would have occurred over the course of these studies, although this may have resulted in lower circulating creatinine and albumin levels. The conclusions drawn from the studies presented here must, however, be considered in the context of a moderate dietary protein intake.

In conclusion, the results of the present studies suggest that 4-week feeding of a diet containing 4.8 g/1000 kcal (4184 kJ) total P, with a Ca:P of 0.6 and formulated to contain 5-2% (3.6 g/1000 kcal (4184 kJ)) SDHP, causes renal dysfunction in healthy adult cats. In addition, in most cats prolonged feeding of a diet with a total dietary P content of 3.6 g/1000 kcal (4184 kJ), Ca:P 0.9, formulated to contain 2.2% (1.5 g/1000 kcal (4184 kJ)) SDHP results in no change in renal function. However, sonographic changes to the kidneys were observed in some individuals, and although the clinical significance of these is not known in a small number renal dysfunction did occur. Multiple sources of evidence suggest that dietary P provided by organic raw materials is less bioavailable than that arising from added inorganic sources, including the SDHP used in the present study. Furthermore, recent studies by our group suggest that diets with a high inclusion of inorganic P and specifically SDHP, along with a Ca:P <1.0, induce a prolonged increase in serum concentration postprandially(30) and that this may be an important factor in the adverse effects observed here. As a NOAEL for dietary P was not established, further work is required to determine both this and the effects of dietary P source and Ca:P ratio have on renal health in healthy adult cats.

Acknowledgements

The authors acknowledge the skills and expertise of colleagues at WALTHAM in the care and training of the cats and for the analysis of samples collected throughout the study. This work was funded by Mars Petcare. The WALTHAM® Centre for Pet Nutrition is a fundamental research centre for Mars Petcare.

J. S., J. Alexander, D. E., M. G., P. M., J. E., R. B. and P. W. conceived the project. J. S., J. Alexander, D. E., P. W. and M. G. developed the overall research plan and had study oversight. J. Alexander, J. S., M. G. and J. Atwal conducted the research and oversaw the analysis of the samples. H. R. carried out and assessed the abdominal ultrasounds and radiographs. R. S. and A. C. performed the statistical analysis. J. Alexander authored the paper with J. S., P. W., M. G., J. Atwal, P. M., J. E. and H. R. J. Alexander, J. S., J. Atwal, R. B., A. C., D. E., M. G., P. M., R. S. and P. W. were employees of Mars Petcare during the study. J. E. and H. R. acted as paid independent consultants for Mars Petcare at the time of the study.

Supplementary material

For supplementary material(s) referred to in this article, please visit https://doi.org/10.1017/S0007114518002751

References

1. O’Brien TD, Osborne CA, et al. (1992) Feline renal failure: questions, answers, questions. Compend Cont Ed Pract Vet 14, 127–152.
2. Elliott D & Lefebvre H (2006) Chronic renal disease: the importance of nutrition. In Encyclopedia of Canine Clinical Nutrition, pp. 252–282 [P Pibot, editor]. Aimargues, France: Royal Canin.
3. DiBartola SP & Willard MD (2006) Disorders of phosphorus: hyperphosphatemia and hyperphosphatemia. In Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice, 3rd ed., pp. 195–209 [SP DiBartola, editor]. St Louis, MO: Elsevier Science.
4. National Research Council (US) (2006) Ad Hoc Committee on Dog and Cat Nutrition. Washington, DC: National Academies Press.
5. FEDIAF-European Pet Food Industry Federation (2016) FEDIAF Nutritional Guidelines for Complete and Complementary Pet Food for Cats and Dogs. Brussels.
6. Association of American Feed Control Officials (2016) American Association of Feed Control Officials Official Publication. Washington, DC: The Association of Feed Control Officials Inc.
7. Pastoor F, Klooster A, Mathot J, et al. (1995) Increasing phosphorus intake reduces urinary concentrations of magnesium and calcium in adult ovariectomized cats fed purified diets. J Nutr 125, 1334–1341.
8. Dobenecker B, Webel A, Reese S, et al. (2018) Effect of a high phosphorus diet on indicators of renal health in cats. J Feline Med Surg 20, 339–345.
9. Siedler S & Dobenecker B (2015) Effect of different P sources in high phosphorus diets with balanced Ca/P ratio on serum PTH, P and calcium levels as well as apparent digestibility of these minerals in dogs. In Proceedings of the 19th ESVCN Congress, 17 September 2015, pp. 17–19.
10. Noori N, Sims JJ, Kopple JD, et al. (2010) Organic and inorganic dietary phosphorus and its management in chronic kidney disease. Iran J Kidney Dis 4, 89–100.
11. Matsuzaki H, Kikuchi T, Kajita Y, et al. (1999) Comparison of various phosphate salts as the dietary phosphorus source on nephrocalcinosis and kidney function in rats. J Nutr Sci Vitaminol 45, 595–608.

12. Finco D, Barsanti J & Brown S (1989) Influence of dietary source of phosphorus on fecal and urinary excretion of phosphorus and other minerals by male cats. Am J Vet Res 50, 263–266.

13. Gutiérrez OM (2013) Sodium- and phosphorus-based food additives: persistent but surmountable hurdles in the management of nutrition in chronic kidney disease. Adv Chronic Kidney Dis 20, 150–156.

14. Marks J, Lee GJ, Nadaraja SP, et al. (2015) Experimental and regional variations in Na+-dependent and Na+-independent phosphate transport along the rat small intestine and colon. Physiol Rep 3, e12281.

15. Davies M, Alborough R, Jones L, et al. (2017) Mineral analysis of complete dog and cat foods in the UK and compliance with European guidelines. Sci Rep 7, 17107.

16. German AJ, Holden SL, Moxham GL, et al. (2006) A simple, reliable tool for owners to assess the body condition of their dog or cat. J Nutr 136, 2031S–2038S.

17. Rokey GJ (1994) Petfood and fishfood extrusion. In The Technology of Extrusion Cooking, pp. 144–189 [ND Frame, editor]. New York: Chapman & Hall.

18. European Union (2008) Official Journal of the European Union, Regulation (EC) N ° 152 / (2009) of the commission of 27/01/2009. In Regulation (EC) No. 152, vol. 152. Brussels: European Union.

19. Robertson WG, Jones JS, Heaton MA, et al. (2002) Predicting the crystallization potential of urine from cats and dogs with respect to calcium oxalate and magnesium ammonium phosphate (struvite). J Nutr 132, 1637S–1641S.

20. Geddes R, Finch N, Elliott J, et al. (2013) Fibroblast growth factor 23 in feline chronic kidney disease. J Vet Intern Med 27, 234–241.

21. Williams T, Elliott J & Syme H (2012) Calcium and phosphate homeostasis in hyperthyroid cats—associations with development of azotaemia and survival time. J Small Anim Pract 53, 561–571.

22. Aronov PA, Hall LM, Dettmer K, et al. (2008) Metabolic profiling of major vitamin D metabolites using Diels–Alder derivatization and ultra-performance liquid chromatography–tandem mass spectrometry. Anal Bioanal Chem 391, 1917–1930.

23. Finch NC, Syme HM, Elliott J, et al. (2011) Glomerular filtration rate estimation by use of a correction formula for slope–intercept plasma iohexol clearance in cats. Am J Vet Res 72, 1652–1659.

24. Von Kossa J (1901) Über die im Organismus künstlich erzeugten Verkalkungen (About calcification that are artificially produced in the organism). Beitr Anat 29, 165.

25. Team RC (2017) R: A Language and Environment for Statistical Computing, Google Scholar.

26. Bates D, Maechler M, Bolker B, et al. (2014) lme4: Linear Mixed-effects Models Using Eigen and S4. https://cran.r-project.org/web/packages/lme4/index.html

27. Hothorn T, Bretz F & Westfall P (2008) Simultaneous inference in general parametric models. Biom J 50, 346–363.

28. Wickham H (2009) ggplot2: Elegant Graphics for Data Analysis. New York, NY: Springer-Verlag.

29. Braun J-P & Lefebvre H (2008) Kidney function and damage. Clin Biochem Domest Anim 6, 485–528.

30. Monaghan K, Nolan B & Libato M (2012) Feline acute kidney injury: I. Pathophysiology, etiology and etiology-specific management considerations. J Feline Med Surg 14, 775–784.

31. Bucknell D (2000) Feline hyperthyroidism: spectrum of clinical presentations and response to carbimazole therapy. Aust Vet J 78, 462–465.

32. Pechereau D, Martel P & Braun J (1997) Plasma erythropoietin concentrations in dogs and cats: reference values and changes with anaemia and/or chronic renal failure. Res Vet Sci 62, 185–188.

33. Lees GE, Brown SA, Elliott J, et al. (2005) Assessment and management of proteinuria in dogs and cats: 2004 ACVIM Forum Consensus Statement (small animal). J Vet Intern Med 19, 377–385.

34. Barber P & Elliott J (1998) Feline chronic renal failure: calcium homeostasis in 80 cases diagnosed between 1992 and 1995. J Small Anim Pract 39, 108–116.

35. Barber P & Elliott J (1996) Study of calcium homeostasis in feline hyperthyroidism. J Small Anim Pract 37, 575–582.

36. Demmel A (2011) Der Einfluss der alimentären Phosphorspeisung auf ausgewählte Nierenfunktionsparameter bei Katzen (The influence of dietary phosphorus supply on selected kidney function parameters in cats). DVM Thesis, Ludwig-Maximilians-Universität, München.

37. Reynolds B, Chetboul V, Nguyen P, et al. (2013) Effects of dietary salt intake on renal function: a 2-year study in healthy aged cats. J Vet Intern Med 27, 507–515.

38. Colthard JC, Staunton RH, Colyer A, et al. (2018) Not all forms of dietary phosphorus are equal: an evaluation of postprandial phosphorus concentrations in the plasma of the cat. Br J Nutr (In the Press).

39. Dobenecker B, Weibel A, Hertel-Böhnhke P, et al. (2013) Effect of high phosphorus intake on renal parameters in cats is influences by phosphorus concentration in urine. In Waltham International Nutritional Sciences Symposium, pp. 35, Portland, OR, 2 October 2013.

40. Hertel-Böhnhke PK & Dobenecker B (2012) A high phosphorus diet with a Ca/P ratio of 0.9/1 affects renal parameters in healthy cats. Eur Soc Vet Comp Nutr Congr 63, 63–64.

41. Blaine J, Chonchol M & Levi M (2014) Renal control of calcium, phosphate, and magnesium homeostasis. Clin J Am Soc Nephrol 10, 1257–1272.

42. Levi M, Kempson S, Lötscher M, et al. (1996) Molecular regulation of renal phosphate transport. J Membr Biol 154, 1–9.

43. Razzouq MS (2009) The FGF23–Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 5, 611–619.

44. Finco D, Brown S, Barsanti J, et al. (1997) Reliability of using random urine samples for “spot” determination of fractional excretion of electrolytes in cats. Am J Vet Res 58, 1184–1187.

45. Russo E, Lees G & Hightower D (1986) Evaluation of renal function in cats, using quantitative urinalysis. Am J Vet Res 47, 1308–1312.

46. Lulich J, Osborne C, Polzin D, et al. (1991) Urine metabolite values in fed and nonfed clinically normal beagles. Am J Vet Res 52, 1573–1578.

47. van den Broek DH, Chang YM, Elliott J, et al. (2018) Prognostic importance of plasma total magnesium in a cohort of cats with azotemic chronic kidney disease. J Vet Intern Med 32, 1539–1571.

48. Rizzoli R, Fleisch H & Bonjour JP (1977) Role of 1,25-dihydroxyvitamin D3 on intestinal phosphate absorption in rats with a normal vitamin D supply. J Clin Invest 60, 639–647.

49. Lefebvre HP, Dossin O, Trumel C, et al. (2008) Fractional excretion tests: a critical review of methods and applications in domestic animals. Vet Clin Pathol 37, 4–20.

50. Nagode LA, Chew DJ & Podell M (1996) Benefits of calcitriol therapy and serum phosphorus control in dogs and cats with
chronic renal failure: both are essential to prevent or suppress toxic hyperparathyroidism. Vet Clin North Am Small Anim Pract 26, 1293–1330.

51. Adler AJ, Ferran N & Berlyne GM (1985) Effect of inorganic phosphate on serum ionized calcium concentration in vitro: a reassessment of the “trade-off” hypothesis. Kidney Int 28, 952–955.

52. IX JH, Anderson CAM, Smits G, et al. (2014) Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study. Am J Clin Nutr 100, 1392–1397.

53. Lamberg-Allardt C, Karp H & Kemi V (2010) Phosphorus and bone. In Nutritional Influences on Bone Health, pp. 87–97 [P. Burckhardt, B Dawson-Hughes and C Weaver, editors]. London: Springer-Verlag.

54. Ferrari SL, Bonjour J-P & Rizzoli R (2005) Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90, 1519–1524.

55. O’Brien CA, Jilka RL, Fu Q, et al. (2005) IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. Am J Physiol Endocrinol Metab 289, E784–E793.

56. Bellido T, Ali AA, Piotkin LI, et al. (2003) Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts; a putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278, 50259–50272.

57. Di Bartola SP (2011) Fluid, Electrolyte, and Acid–Base Disorders in Small Animal Practice. St Louis, MO: Elsevier Health Sciences.

58. Gutiérrez OM (2010) Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90, 1519–1524.

59. Kemi VE, Rita HJ, Kärkkäinen MU, et al. (2009) Habitual high phosphorus intakes and foods with phosphate additives negatively affect serum parathyroid hormone concentration: a cross-sectional study on healthy premenopausal women. Public Health Nutr 12, 1885–1892.

60. Heaney RP & Recker RR (1982) Effects of nitrogen, phosphorus, and caffeine on calcium balance in women. J Lab Clin Med 99, 46–55.

61. Klein L, LaFertty FW, Pearson OH, et al. (1964) Correlation of urinary hydroxyproline, serum alkaline phosphatase and skeletal calcium turnover. Metabolism 13, 272–284.

62. Landau D, Krymko H, Shaley H, et al. (2007) Transient severe metastatic calcification in acute renal failure. Pediatr Nephrol 22, 607–611.

63. McLeland SM, Lunn KF, Duncan CG, et al. (2014) Retrieved article. Among serum creatinine, serum gastrin, calcium–phosphorus product, and uremic gastropathy in cats with chronic kidney disease. J Vet Intern Med 28, 827–857.

64. Leichowski C, Osborne CA, Lulich JP, et al. (2001) Association between dietary factors and calcium oxalate and magnesium ammonium phosphate urolithiasis in cats. J Am Vet Med Assoc 219, 1228–1237.

65. Evasive M, Remillard R & Bartges J (2016) Understanding urinary relative supersaturation. Clinician’s Brief, April 2016. https://www.cliniciansbrief.com/article/understanding-urinary-relative-supersaturation

66. Culich J, Berent A, Adams L, et al. (2016) ACVIM small animal consensus recommendations on the treatment and prevention of uroliths in dogs and cats. J Vet Intern Med 30, 1564–1574.

67. Böswald L, Kienzle E & Dobenecker B (2018) Observation of uroliths in dogs and cats. Vet Med Assoc 22, 369–387.

68. Plantinga E, Everts H, Kastelein A, et al. (2014) Crystal-associated urinary relative supersaturation. J Vet Med Sci 76, 1014–1021.

69. Evan AP, Remillard R & Bartges J (2016) Understanding urinary relative supersaturation. Clinician’s Brief, April 2016. https://www.cliniciansbrief.com/article/understanding-urinary-relative-supersaturation

70. Krambeck AE, Handa SE, Evans AP, et al. (2010) Brushite stone disease as a consequence of lithotripsy? Urol Res 38, 293–299.

71. Evan AP, Lingeman JE, Coe FL, et al. (2005) Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int 67, 576–591.

72. Hall JA, Yerramilli M, Obare E, et al. (2017) Serum concentrations of symmetric dimethylarginine and creatinine in cats with kidney stones. PLOS ONE 12, e0174854.

73. Plantinga E, Everts H, Kastelein A, et al. (2005) Retrospective study of the survival of cats with acquired chronic renal insufficiency offered different commercial diets. Vet Rec 157, 185–187.

74. Böswald L, Kienzle E & Dobenecker B (2018) Observation about phosphorus and protein supply in cats and dogs prior to the diagnosis of chronic kidney disease. J Anim Physiol Anim Nutr 102, 31–36.

75. Laflamme DP (2001) Determining metabolizable energy content in commercial pet foods. J Anim Physiol Anim Nutr 85, 222–230.